AKTS
insider transactionsAktis Oncology, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 6 different insiders made open-market purchases in the last 365 days, totalling $114.3M.
Net shares · 365d
+6.4M
6.4M buy · 0 sell
Net value · 365d
$114.3M
$114.3M in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
9
6.4M buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
37.9K sh
Own New
-
Exercise·C
Director,TenPercentOwner
$0
411.8K sh
Own New
-
Exercise·C
Director,TenPercentOwner
$0
3.6M sh
Own New
-
Exercise·C
Director,TenPercentOwner
$0
101.2K sh
Own New
-
Exercise·C
Director,TenPercentOwner
$0
14.8M sh
Own New
-
Buy·P
Director,TenPercentOwner
$14.6M
812.5K sh · $18.00
Own +17%
-
Exercise·C
Director,TenPercentOwner
—
134.8K sh
Own New
-
Buy·P
Director,TenPercentOwner
$405.8K
22.5K sh · $18.00
Own +17%
-
Exercise·C
Director,TenPercentOwner
—
4.9M sh
Own New
-
Exercise·C
Director
$0
50.0K sh
Own New
-
Exercise·C
Director
$0
24.7K sh
Own New
-
Exercise·C
Director
—
19.6K sh
Own New
-
Exercise·C
Director
—
102.5K sh
Own New
-
Exercise·C
Director
—
86.2K sh
Own New
-
Exercise·C
Director
—
965.2K sh
Own New
-
Exercise·C
Director
—
2.4M sh
Own New
-
Exercise·C
Director
—
488.9K sh
Own New
-
Exercise·C
Director
—
997.3K sh
Own New
-
Exercise·C
Director
—
9.9M sh
Own New
-
Buy·P
Director
$2.6M
144.4K sh · $18.00
Own +71%
-
Exercise·C
Director
—
2.3M sh
Own New
-
Exercise·C
Director
—
202.9K sh
Own New
-
Exercise·C
Director
—
128.5K sh
Own New
-
Buy·P
Director
$37.4M
2.1M sh · $18.00
Own +91%
-
Exercise·C
TenPercentOwner
$0
3.6M sh
Own New
-
Exercise·C
TenPercentOwner
$0
101.2K sh
Own New
-
Exercise·C
TenPercentOwner
$0
411.8K sh
Own New
-
Exercise·C
TenPercentOwner
$0
14.8M sh
Own New
-
Buy·P
TenPercentOwner
$14.6M
812.5K sh · $18.00
Own +17%
-
Exercise·C
TenPercentOwner
—
134.8K sh
Own New
-
Buy·P
TenPercentOwner
$405.8K
22.5K sh · $18.00
Own +17%
-
Exercise·C
TenPercentOwner
—
4.9M sh
Own New
-
Exercise·C
Director,TenPercentOwner
$0
10.2M sh
Own New
-
Exercise·C
Director,TenPercentOwner
$0
2.7M sh
Own New
-
Exercise·C
Director,TenPercentOwner
$0
2.3M sh
Own New
-
Exercise·C
Director,TenPercentOwner
—
716.9K sh
Own +22%
-
Exercise·C
Director,TenPercentOwner
—
597.4K sh
Own New
-
Buy·P
Director,TenPercentOwner
$4.2M
232.9K sh · $18.00
Own +6%
-
Exercise·C
Director,TenPercentOwner
—
2.7M sh
Own +450%
-
Exercise·C
TenPercentOwner
$0
22.5M sh
Own New
-
Exercise·C
TenPercentOwner
$0
5.0M sh
Own New
-
Exercise·C
TenPercentOwner
$0
6.0M sh
Own New
-
Exercise·C
TenPercentOwner
—
5.9M sh
Own +357%
-
Exercise·C
TenPercentOwner
—
1.6M sh
Own +21%
-
Buy·P
TenPercentOwner
$20.0M
1.1M sh · $18.00
Own +12%
-
Exercise·C
TenPercentOwner
—
1.3M sh
Own +385%
-
Exercise·C
MPM ONCOLOGY INNOVATIONS FUND LP
TenPercentOwner
$0
5.0M sh
Own New
-
Exercise·C
MPM ONCOLOGY INNOVATIONS FUND LP
TenPercentOwner
$0
6.0M sh
Own New
-
Exercise·C
MPM ONCOLOGY INNOVATIONS FUND LP
TenPercentOwner
$0
22.5M sh
Own New
-
Buy·P
MPM ONCOLOGY INNOVATIONS FUND LP
TenPercentOwner
$20.0M
1.1M sh · $18.00
Own +12%
-
Exercise·C
MPM ONCOLOGY INNOVATIONS FUND LP
TenPercentOwner
—
1.3M sh
Own +385%
-
Exercise·C
MPM ONCOLOGY INNOVATIONS FUND LP
TenPercentOwner
—
5.9M sh
Own +357%
-
Exercise·C
MPM ONCOLOGY INNOVATIONS FUND LP
TenPercentOwner
—
1.6M sh
Own +21%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 15, 2026 | Glenn Gormley | Grant A | 37.9K | $0 |
| Jan 12, 2026 | Kim Helen Susan | Exercise C | 411.8K | $0 |
| Jan 12, 2026 | Kim Helen Susan | Exercise C | 3.6M | $0 |
| Jan 12, 2026 | Kim Helen Susan | Exercise C | 101.2K | $0 |
| Jan 12, 2026 | Kim Helen Susan | Exercise C | 14.8M | $0 |
| Jan 12, 2026 | Kim Helen Susan | Buy P | 812.5K | $14.6M |
| Jan 12, 2026 | Kim Helen Susan | Exercise C | 134.8K | — |
| Jan 12, 2026 | Kim Helen Susan | Buy P | 22.5K | $405.8K |
| Jan 12, 2026 | Kim Helen Susan | Exercise C | 4.9M | — |
| Jan 12, 2026 | Segal Lloyd Mitchell | Exercise C | 50.0K | $0 |
| Jan 12, 2026 | Segal Lloyd Mitchell | Exercise C | 24.7K | $0 |
| Jan 12, 2026 | Segal Lloyd Mitchell | Exercise C | 19.6K | — |
| Jan 12, 2026 | NODELMAN OLEG | Exercise C | 102.5K | — |
| Jan 12, 2026 | NODELMAN OLEG | Exercise C | 86.2K | — |
| Jan 12, 2026 | NODELMAN OLEG | Exercise C | 965.2K | — |
| Jan 12, 2026 | NODELMAN OLEG | Exercise C | 2.4M | — |
| Jan 12, 2026 | NODELMAN OLEG | Exercise C | 488.9K | — |
| Jan 12, 2026 | NODELMAN OLEG | Exercise C | 997.3K | — |
| Jan 12, 2026 | NODELMAN OLEG | Exercise C | 9.9M | — |
| Jan 12, 2026 | NODELMAN OLEG | Buy P | 144.4K | $2.6M |
| Jan 12, 2026 | NODELMAN OLEG | Exercise C | 2.3M | — |
| Jan 12, 2026 | NODELMAN OLEG | Exercise C | 202.9K | — |
| Jan 12, 2026 | NODELMAN OLEG | Exercise C | 128.5K | — |
| Jan 12, 2026 | NODELMAN OLEG | Buy P | 2.1M | $37.4M |
| Jan 12, 2026 | VIDA VENTURES II-A, LLC | Exercise C | 3.6M | $0 |
| Jan 12, 2026 | VIDA VENTURES II-A, LLC | Exercise C | 101.2K | $0 |
| Jan 12, 2026 | VIDA VENTURES II-A, LLC | Exercise C | 411.8K | $0 |
| Jan 12, 2026 | VIDA VENTURES II-A, LLC | Exercise C | 14.8M | $0 |
| Jan 12, 2026 | VIDA VENTURES II-A, LLC | Buy P | 812.5K | $14.6M |
| Jan 12, 2026 | VIDA VENTURES II-A, LLC | Exercise C | 134.8K | — |
| Jan 12, 2026 | VIDA VENTURES II-A, LLC | Buy P | 22.5K | $405.8K |
| Jan 12, 2026 | VIDA VENTURES II-A, LLC | Exercise C | 4.9M | — |
| Jan 12, 2026 | Foley Todd | Exercise C | 10.2M | $0 |
| Jan 12, 2026 | Foley Todd | Exercise C | 2.7M | $0 |
| Jan 12, 2026 | Foley Todd | Exercise C | 2.3M | $0 |
| Jan 12, 2026 | Foley Todd | Exercise C | 716.9K | — |
| Jan 12, 2026 | Foley Todd | Exercise C | 597.4K | — |
| Jan 12, 2026 | Foley Todd | Buy P | 232.9K | $4.2M |
| Jan 12, 2026 | Foley Todd | Exercise C | 2.7M | — |
| Jan 12, 2026 | GADICKE ANSBERT | Exercise C | 22.5M | $0 |
| Jan 12, 2026 | GADICKE ANSBERT | Exercise C | 5.0M | $0 |
| Jan 12, 2026 | GADICKE ANSBERT | Exercise C | 6.0M | $0 |
| Jan 12, 2026 | GADICKE ANSBERT | Exercise C | 5.9M | — |
| Jan 12, 2026 | GADICKE ANSBERT | Exercise C | 1.6M | — |
| Jan 12, 2026 | GADICKE ANSBERT | Buy P | 1.1M | $20.0M |
| Jan 12, 2026 | GADICKE ANSBERT | Exercise C | 1.3M | — |
| Jan 12, 2026 | MPM ONCOLOGY INNOVATIONS FUND LP | Exercise C | 5.0M | $0 |
| Jan 12, 2026 | MPM ONCOLOGY INNOVATIONS FUND LP | Exercise C | 6.0M | $0 |
| Jan 12, 2026 | MPM ONCOLOGY INNOVATIONS FUND LP | Exercise C | 22.5M | $0 |
| Jan 12, 2026 | MPM ONCOLOGY INNOVATIONS FUND LP | Buy P | 1.1M | $20.0M |
| Jan 12, 2026 | MPM ONCOLOGY INNOVATIONS FUND LP | Exercise C | 1.3M | — |
| Jan 12, 2026 | MPM ONCOLOGY INNOVATIONS FUND LP | Exercise C | 5.9M | — |
| Jan 12, 2026 | MPM ONCOLOGY INNOVATIONS FUND LP | Exercise C | 1.6M | — |
About AKTS insider trading
This page tracks insider transactions for Aktis Oncology, Inc. (AKTS) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.